• A
• A
• A

Early Morning Colonoscopies Detect More Polyps (11/11/2009)
Among patients undergoing colonoscopy at a Veteran’s Administration (VA) medical center, a greater number of polyps was detected among patients seen early in the morning than among patients seen later in the day. The reasons for this are uncertain, but it’s possible that the lower rate of polyp detection later in the day is the result of provider fatigue or less complete bowel preparation. These results were published in Clinical Gastroenterology and Hepatology.

Daily Aspirin Prevents Colorectal Cancer in Lynch Syndrome (10/05/2009)
Daily aspirin may prevent the incidence of cancer in individuals who are genetically predisposed to hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch Syndrome, according to the results of a study presented September 21, 2009 at Europe’s largest cancer congress, ECCO 15-ESMO 34, in Berlin.

First-line Vectibix Modestly Improves Colorectal Cancer Outcome (09/25/2009)
Among patients with metastatic colorectal cancer, initial treatment with a combination of chemotherapy and Vectibix® (panitumumab) delays cancer progression by 1.6 months compared with chemotherapy alone. This benefit, which was reported at a major European cancer conference, only applied to patients whose tumors did not contain a mutation in the KRAS gene.

Vectibix® Delays Progression of Metastatic Colorectal Cancer (09/23/2009)
Among patients with previously treated, metastatic colorectal cancer, the addition of the targeted therapy Vectibix® (panitumumab) to chemotherapy delayed cancer progression. This benefit was only observed in patients whose tumors did not contain a mutation in the KRAS gene. These results were presented at a major European cancer conference.

Cancer Caregivers Devote Substantial Time and Effort (09/09/2009)
On average, informal caregivers of cancer patients devote more than eight hours per day to caregiving. These results were published in Cancer.

▪ More...

Cancer Caregivers Devote Substantial Time and Effort (09/09/2009)
On average, informal caregivers of cancer patients devote more than eight hours per day to caregiving. These results were published in Cancer.

Diet and Exercise Intervention Produces Results in Long-term Survivors (07/14/2009)
Long-term survivors of breast, colorectal, and prostate cancer who participated in a year-long home-based diet and exercise intervention reported a smaller decline in physical function compared with their counterparts who did not participate in the program, according to the results of a study published in the Journal of the American Medical Association.

Oncotype DX® Colon Cancer Test Predicts Recurrence Risk (06/03/2009)
According to the results of a study that will be presented at the 2009 annual meeting of the American Society of Clinical Oncology (ASCO), the Oncotype DX® colon cancer test estimates the risk of cancer recurrence among patients with Stage II colon cancer. This test may eventually help guide colon cancer treatment decisions.

No Benefit of Avastin® in Early-stage Colon Cancer (06/01/2009)
According to the results of a Phase III clinical trial presented at the 2009 annual meeting of the American Society of Clinical Oncology (ASCO), addition of the targeted therapy Avastin® (bevacizumab) to post-surgery chemotherapy does not improve disease-free survival among patients with early-stage colon cancer. These results were previously made available in a press release from Roche.

Addition of Eloxatin® to Adjuvant Chemotherapy Improves Colon Cancer Outcomes (05/22/2009)
The addition of Eloxatin® (oxaliplatin) to adjuvant (post-surgery) chemotherapy with fluorouracil and leucovorin improves survival among patients with Stage II or Stage III colon cancer. The results of this Phase III clinical trial were published in the Journal of Clinical Oncology.

▪ More...

Early Morning Colonoscopies Detect More Polyps (11/11/2009)
Among patients undergoing colonoscopy at a Veteran’s Administration (VA) medical center, a greater number of polyps was detected among patients seen early in the morning than among patients seen later in the day. The reasons for this are uncertain, but it’s possible that the lower rate of polyp detection later in the day is the result of provider fatigue or less complete bowel preparation. These results were published in Clinical Gastroenterology and Hepatology.

Daily Aspirin Prevents Colorectal Cancer in Lynch Syndrome (10/05/2009)
Daily aspirin may prevent the incidence of cancer in individuals who are genetically predisposed to hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch Syndrome, according to the results of a study presented September 21, 2009 at Europe’s largest cancer congress, ECCO 15-ESMO 34, in Berlin.

False-positive Results Are Common with Cancer Screening (07/20/2009)
The risk of obtaining a false-positive result from screening for prostate, lung, colorectal, and ovarian cancer is high and becomes cumulatively higher with ongoing screening—after 14 screening tests, the cumulative risk of a false-positive is 60.4% for men and 48.8% for women, according to the results of a study published in the Annals of Family Medicine.

Diet and Lifestyle Choices Key to Preventing Colorectal Cancer (07/09/2009)
Exercise, diet, and lifestyle choices are key factors in preventing colon cancer, according to the results of a study published in the International Journal of Cancer.

CT Colonography May Be Appropriate Screening Test for Some High-risk Individuals (06/22/2009)
Among people at increased risk of colorectal cancer, computed tomographic (CT) colonography correctly classified 85% of the people with advanced adenomas or cancer and 88% of the people without advanced adenomas or cancer. These results were published in the Journal of the American Medical Association.

▪ More...

First-line Vectibix Modestly Improves Colorectal Cancer Outcome (09/25/2009)
Among patients with metastatic colorectal cancer, initial treatment with a combination of chemotherapy and Vectibix® (panitumumab) delays cancer progression by 1.6 months compared with chemotherapy alone. This benefit, which was reported at a major European cancer conference, only applied to patients whose tumors did not contain a mutation in the KRAS gene.

Vectibix® Delays Progression of Metastatic Colorectal Cancer (09/23/2009)
Among patients with previously treated, metastatic colorectal cancer, the addition of the targeted therapy Vectibix® (panitumumab) to chemotherapy delayed cancer progression. This benefit was only observed in patients whose tumors did not contain a mutation in the KRAS gene. These results were presented at a major European cancer conference.

Addition of Vectibix® to Second-line Chemotherapy Improves Progression-free Survival in Metastatic Colorectal Cancer (08/24/2009)
Among patients with previously treated, metastatic colorectal cancer, the addition of the targeted therapy Vectibix® (panitumumab) to chemotherapy delayed cancer progression. This benefit was only observed in patients whose tumors did not contain a mutation in the KRAS gene. These results were made available in a press release from Amgen.

Addition of Vectibix® to First-line Chemotherapy Improves Progression-free Survival in Metastatic Colorectal Cancer (08/10/2009)
Among patients with metastatic colorectal cancer, the addition of the targeted therapy Vectibix® (panitumumab) to chemotherapy delayed cancer progression. This benefit was only observed in patients whose tumors did not contain a mutation in the KRAS gene. These results were made available in a press release from Amgen.

Sutent® Fails to Show Benefit in Metastatic Colorectal Cancer (07/01/2009)
The combination of the targeted therapy Sutent® (sunitinib) and FOLFIRI chemotherapy did not result in better progression-free survival than FOLFIRI alone among patients with metastatic colorectal cancer, prompting a Phase III clinical trial of the combination treatment to be stopped early. This information was made available in a press release from Pfizer.

▪ More...